The Effect of Pravastatin on Insulin Resistance in Hyperglycemic Patients.
- Author:
Yong Jin JEONG
1
;
Jung Min KIM
;
Seung Jae JANG
;
Jun Hee BANG
;
Young Gon JUNG
;
Sung Taek KIM
;
Soon Hyoung KANG
;
Jong In CHOI
;
Soo Sung KIM
;
Mi Yeon KANG
Author Information
- Publication Type:Original Article
- Keywords: Homeostasis model assessment of insulin resistance; Insulin resistance; Pravastatin; Prediabetic state; Quantitive insulin sensitivity check index
- MeSH: Cholesterol; Fasting; Glucose; Homeostasis; Humans; Hyperglycemia; Insulin Resistance*; Insulin*; Lipoproteins; Pravastatin*; Prediabetic State; Prevalence; Saints
- From:Journal of Korean Diabetes 2017;18(1):53-61
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: The effect of pravastatin on insulin resistance (IR) is controversial and poorly studied in prediabetes. METHODS: This study was performed in hyperglycemic patients at Saint Carollo Hospital from January 1, 2013 to December 31, 2015. Among them, we selected 40 patients (24 prediabetes and 16 new onset diabetes [NOD]) who had been treated with pravastatin 20 mg daily for 2 or 4 months and in whom fasting insulin and fasting glucose had been measured before and after administration of pravastatin. IR was defined as a fasting insulin level ≥ 12.94 µU/mL, homeostasis model for IR (HOMA-IR) ≥ 3.04 or quantitative insulin sensitivity check index (QUICKI) ≤ 0.32. RESULTS: Pravastatin treatment decreased total cholesterol and low-density lipoprotein cholesterol levels by 25.2% and 32.3% respectively (P = 0.000 for all), but did not affect fasting insulin level, HOMA-IR, or QUICKI in total, prediabetes, and NOD groups. Prevalence of IR was significantly different between prediabetes and NOD groups both before and after pravastatin treatment (0% versus 37.5%, P = 0.001), but pravastatin treatment did not affect the prevalence of IR in the prediabetes or NOD group. Fasting glucose level was not significantly different before and after pravastatin treatment in prediabetes (106.8 ± 6.4 mg/dL versus 103.8 ± 8.4 mg/dL, P = 0.223) but was significantly different in the NOD group (171.5 ± 70.1 mg/dL versus 124.4 ± 26.7 mg/dL, P = 0.017). CONCLUSION: Pravastatin treatment did not affect IR or fasting glucose level in hyperglycemic patients. Therefore, we suggest pravastatin can be prescribed to hypercholesterolemic patients with hyperglycemia.
